Atrium Health Wake Forest Baptist

Running trials

• Not yet recruiting

  Supporting Health and Empowerment Through Contingency Management and Affect Regulation

  NCT07792161· Wake Forest University Health Sciences· Source

• Not yet recruiting

  Evaluating and Promoting Resilience in Adolescents With Tourette Syndrome

  NCT07905898· Wake Forest University Health Sciences· Source

• Recruiting

  The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma

  NCT07560826· Phase 2· Wake Forest University Health Sciences· Source

• Recruiting

  INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

  NCT06965504· Abiomed Inc.· Source

• Not yet recruiting

  Cilostazol for Prevention of Recurrent Stroke Trial

  NCT07174414· Phase 3· Stanford University· Source

• Recruiting

  WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

  NCT07558265· Ohio State University· Source

• Recruiting

  Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

  NCT07324031· AtaCor Medical, Inc.· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

• Recruiting

  A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients

  NCT07322367· Wake Forest University Health Sciences· Source

• Recruiting

  Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

  NCT07136415· Phase 4· Brigham and Women's Hospital· Source

• Recruiting

  Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Recruiting

  Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

  NCT06837181· Jaeb Center for Health Research· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· BeOne Medicines· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· Phase 3· BeOne Medicines· Source

• Active, not recruiting

  Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening

  NCT06821009· Digital Health Navigation Solutions, Inc· Source

• Recruiting

  A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  NCT06747351· Phase 3· Takeda· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  NCT06742996· Phase 3· BeOne Medicines· Source

• Recruiting

  StrokeNet Thrombectomy Endovascular Platform

  NCT06289985· Medical University of South Carolina· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

  NCT07701161· Neurogen Biomarking LLC· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

  NCT06616194· Phase 3· Pfizer· Source

• Recruiting

  A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

  NCT06422923· Phase 1/2· Neurona Therapeutics· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  NCT06439082· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Nicole Hamblett· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Gilead Sciences· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

• Recruiting

  Tracking Results of Ablations to Combat AF Registry Generation 2

  NCT05111015· AtriCure, Inc.· Source

• Recruiting

  A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

  NCT05646381· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Incremental Hemodialysis: The TwoPlus Trial

  NCT05828823· Wake Forest University Health Sciences· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Active, not recruiting

  Impairments That Affect Correct Inhaler Use in COPD

  NCT06135324· COPD Foundation· Source

• Active, not recruiting

  Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

  NCT06141473· Phase 3· Sanofi· Source

• Recruiting

  A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  NCT06034002· Phase 1· Incyte Corporation· Source

• Recruiting

  IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  NCT06119685· Phase 1/2· Indapta Therapeutics, INC.· Source

• Active, not recruiting

  To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

  NCT05908084· Phase 3· Humacyte, Inc.· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older

  NCT05858034· Wake Forest University Health Sciences· Source

• Recruiting

  Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  NCT05826535· Phase 1/2· Lyell Immunopharma, Inc.· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction

  NCT05525663· Wake Forest University Health Sciences· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

  NCT05481151· Phase 3· PharmaEssentia· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

  NCT05317858· Phase 3· InSightec· Source

• Active, not recruiting

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

  NCT05047172· Phase 3· University of Florida· Source

Showing 50 of 73.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Stroke3 recruiting
• Atrial fibrillation2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Cystic fibrosis2 recruiting
• Epilepsy2 recruiting
• HIV2 recruiting
• Lung cancer2 recruiting
• Myasthenia gravis2 recruiting
• Alzheimer disease1 recruiting
• Aortic stenosis1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• COPD1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Glioblastoma1 recruiting
• Insomnia1 recruiting
• Mantle cell lymphoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Sarcoma1 recruiting
• Sickle cell disease1 recruiting
• Sjögren's disease1 recruiting
• Tourette syndrome1 recruiting
• Triple-negative breast cancer1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Withdrawn

  SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 Diabetes

  NCT06719531· Medtronic MiniMed, Inc.· Source

• Withdrawn

  Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease

  NCT06169826· Phase 4· Wake Forest University Health Sciences· Source

• Terminated

  A Study of SGN-MesoC2 in Advanced Solid Tumors

  NCT06466187· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  Strategy for Improving Stroke Treatment Response

  NCT05948566· Phase 2· Translational Sciences, Inc.· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Phase 2· Kowa Research Institute, Inc.· Source

• Completed

  Storytelling To Prevent Obesity and Encourage Responsive Feeding Practices in Young Children

  NCT05994924· Wake Forest University Health Sciences· Source

• Completed

  Feasibility of a Colorectal Cancer Screening Web App in Primary Care Patients

  NCT06241768· Digital Health Navigation Solutions, Inc· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Biosense Webster, Inc.· Source

• Terminated

  A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

  NCT05983133· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Cereset Research Long-Term Healthcare Worker Study

  NCT05994261· Wake Forest University Health Sciences· Source

• Completed

  A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06045221· Phase 3· Eli Lilly and Company· Source

• Completed

  Tools for Anxiety and Depression Screening in Epilepsy

  NCT05864612· Wake Forest University Health Sciences· Source

• Completed

  Perioperative Monitoring of Cardiac Surgery Patients With the Vitalstream Physiological Monitor

  NCT05905536· Wake Forest University Health Sciences· Source

• Completed

  Collaborative Care in Posttraumatic Epilepsy

  NCT05353452· Wake Forest University Health Sciences· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Withdrawn

  A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

  NCT05128344· Phase 3· Amzell· Source

• Completed

  Steps for Epilepsy

  NCT05359003· Wake Forest University Health Sciences· Source

• Completed

  Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

  NCT05615220· Phase 3· Emalex Biosciences Inc.· Source

• Completed

  Observational Study Comparing Home to Office Spirometry

  NCT05285410· Chris Goss· Source

• Completed

  Efficacy in iNPH Shunting (PENS) Trial

  NCT05081128· Johns Hopkins University· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Scholar Rock, Inc.· Source

• Completed

  Monitoring and Testing of Blood Pressure in Postpartum Women

  NCT05236725· Wake Forest University Health Sciences· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Digital Outreach Intervention for Lung Cancer Screening

  NCT04083859· Wake Forest University Health Sciences· Source

• Completed

  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

  NCT05151731· Phase 2· Hoffmann-La Roche· Source

• Completed

  Electronic Frailty Index (eFI)Cacious-Diabetes Care

  NCT05047237· Wake Forest University Health Sciences· Source

• Completed

  Dyad Plus Effectiveness/Feasibility

  NCT04036331· Wake Forest University Health Sciences· Source

• Completed

  Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

  NCT04873934· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

  NCT04666259· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

  NCT04410978· Phase 3· Sanofi· Source

• Terminated

  A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

  NCT04254107· Phase 1· Seagen Inc.· Source

• Completed

  Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

  NCT03532295· Phase 2· Washington University School of Medicine· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Washington University School of Medicine· Source

• Completed

  A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

  NCT06771271· Phase 1· Hoffmann-La Roche· Source

• Completed

  Sleep for Stroke Management and Recovery Trial

  NCT03812653· University of Michigan· Source

• Completed

  Assessing Patient Anxiety During Mohs Micrographic Surgery

  NCT03756792· Wake Forest University Health Sciences· Source

• Completed

  Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

  NCT03496805· Phase 2· Wake Forest University Health Sciences· Source

• Terminated

  Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

  NCT03646123· Phase 2· Seagen Inc.· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Gyroscope Therapeutics Limited· Source

• Completed

  Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

  NCT03250338· Phase 3· Arog Pharmaceuticals, Inc.· Source

• Completed

  DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

  NCT03529110· Phase 3· Daiichi Sankyo· Source

• Terminated

  A Study of Soticlestat in Adults and Children With Rare Epilepsies

  NCT03635073· Phase 2· Takeda· Source

• Completed

  Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

  NCT03472664· Wake Forest University Health Sciences· Source

• Completed

  Hidradenitis Suppurativa Mail Survey

  NCT03572738· Wake Forest University Health Sciences· Source

• Completed

  A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

  NCT02615691· Phase 3· Baxalta now part of Shire· Source

• Terminated

  Reliability of Pupil Response to Acute Pain

  NCT02628314· Wake Forest University Health Sciences· Source

Showing 50 of 51.

Conditions

Diseases this institution publishes on or runs trials for.

• Myeloproliferative neoplasms6 works · 6 trials
• Tourette syndrome3 works · 2 trials